קסניה ונצ'ר קפיטל בע"מ
("החברה")

13 במאי 2021

לכבוד
רשות ניירות ערך
www.isa.gov.il

לכבוד
הבורסה לניירות ערך בת"א
www.tase.co.il

מהות האירוע: **פוליפיד בע"מ (להלן: "פוליפיד") – דיווח על תוצאות כספיות לרבעון הראשון 2021**

החברה מתכבדת לדווח כי פוליפיד פרסמה את תוצאותיה הכספיות לרבעון הראשון של שנת 2021, ("**תקופת הדוח**") וכן מידע לגבי פעילותה. להלן עיקרי הנתונים:

עיקרי התוצאות הכספיות בתקופת הדוח:

- הפסד נקי בסך של 8.7 מיליון דולר בהשוואה להפסד נקי בסך של 5.9 מיליון דולר בתקופה המקבילה אשתקד.
- הוצאות מו"פ בסך של 6 מיליון דולר בהשוואה להוצאות מו"פ בסך של 3.4 מיליון דולר בתקופה המקבילה אשתקד. העלייה בתקופת הדוח נבעה כתוצאה מהניסויים SHILD I, ו - SHILD II בפאזה השלישית.
- הוצאות הנהלה וכלליות בסך של 2.1 מיליון דולר, בהשוואה להוצאות הנהלה וכלליות בסך של 0.7 מיליון דולר בתקופה המקבילה אשתקד. העלייה בתקופת הדוח נבעה כתוצאה מעלייה בעלויות ביטוח דירקטורים ונושאי משרה בעקבות ההנפקה לציבור של מניות פוליפיד, וכן מתגמול מבוסס מניות.

יתרות מזומנים:

נכון ליום 31 במרץ 2021 יתרת המזומנים ושווה מזומנים, פיקדונות לזמן קצר ולזמן ארוך של פוליפיד עמד על סך של 61.4 מיליון דולר, בהשוואה ליתרות בסך של 66.6 מיליון דולר ביום 31 בדצמבר 2020.

פוליפיד מעריכה כי יתרת המזומנים שלה תאפשר את מימון הפעילות שלה מעבר לשנת 2021.

מידע על פעילות פוליפיד:

- גיוס החולים בשני הניסויים - SHILD I ו – SHILD II מתקדם כמתוכנן, ועד היום גויסו לניסוי SHILD I כמעט 200 חולים.

- הקמת יכולת הייצור של פוליפיד הושלמה, ויש ביכולתה לייצר כמות מספקת של D-PLEX100 שתאפשר לספק את הביקוש הצפוי למוצר לתקופה של 30 החודשים הראשונים של שיווקו.

ההערכות שלעיל הינן בגדר מידע צופה פני עתיד, כהגדרת מונח זה בחוק ניירות ערך, התשכ"ח-1968, המבוסס על הערכות ותחזיות של פוליפיד. אין כל וודאות להתממשות הערכות אלו וזאת, בין היתר, בשל גורמים שאינם בשליטת פוליפיד.

למיטב ידיעת החברה, פוליפיד מפתחת טכנולוגית הובלת תרופות בשם PLEX אשר מאפשרת שחרור מקומי, מושהה ומבוקר של מינוני תרופה יעילים לאורך זמן. מוצר הדגל של פוליפיד הוא D-PLEX100, אשר מאפשר שחרור מבוקר ולאורך זמן של אנטיביוטיקה, בכדי למנוע זיהומים שלאחר ניתוחי חזה ובטן. שתי האפליקציות של D-PLEX100 נמצאות בשלב הפאזה השלישית של המחקר הקליני.
לפרטים נוספים אודות פוליפיד, ראו סעיף 9.3 לפרק א' לדוח התקופתי של החברה שפורסם ביום 26 במרץ 2021, מס' אסמכתא 2021-01-048501 (מידע זה מהווה הכללה על דרך ההפניה).

מצ"ב לדיווח זה, הדיווח שפרסמה פוליפיד באתר ה- NASDAQ.

בכבוד רב,

קסניה ונצ'ר קפיטל בע"מ

באמצעות: אלי סורזון, מנכ"ל וסמנכ"ל כספים

PolyPid Ltd. Reports First Quarter 2021 Financial Results and Provides Corporate Update

- *Recruitment Progressing as Planned with Nearly 200 Patients Enrolled into Phase 3 SHIELD I Trial of D-PLEX$_{100}$ in Abdominal Surgery*

- *Recruitment Rate in SHIELD I trial Doubled in the Last Three Weeks*

- *Manufacturing Facility Now Fully Scaled Up and Capable of Supporting at Least First 30 Months of Anticipated Commercial Demand for D-PLEX$_{100}$*

- *Conference Call Scheduled for Today at 8:30 AM ET*

PETAH TIKVA, Israel, May 12, 2021 -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics, today provided a corporate update and reported financial results for the three months ended March 31, 2021.

Recent Corporate Highlights:

- Recruitment progressing as planned with nearly 200 patients enrolled into the ongoing Phase 3 SHIELD I (**S**urgical site **H**ospital-acquired **I**nfection Pr**E**vention with **L**ocal **D**-plex) study, the first of two ongoing Phase 3 clinical trials of the Company's lead product candidate D-PLEX$_{100}$, for the prevention of surgical site infections (SSIs) in abdominal surgery (soft tissue).
- The Company plans to enroll 616-900 patients undergoing high priority operations in 60 centers in the United States, Europe and Israel. Following the enrollment of approximately 500 patients, the study design provides for a blinded sample size re-estimation.
- Enrollment is also advancing as anticipated in SHIELD II, the second of two Phase 3 clinical trials for D-PLEX$_{100}$ in abdominal surgery (soft tissue). SHIELD II will enroll approximately 900-1,400 patients across 60 centers in the United States, Europe and Israel and has broader eligibility criteria, including minimally invasive surgical procedures.
- Manufacturing facility is now fully scaled up and capable of producing the first 30 months of anticipated commercial demand for D-PLEX$_{100}$.
- Continued to generate compelling preclinical data from the Company's new OncoPLEX intra-tumoral cancer therapy program. OncoPLEX utilizes PolyPid's PLEX technology in the intra-operative tumor resection setting to provide prolonged and controlled exposure to docetaxel within the tumor resected site, which is important to prevent local tumor recurrence and the potential spreading of cancer cells.

"We have made significant progress advancing our promising development programs and continuing our evolution towards successful commercialization," said Amir Weisberg, PolyPid's Chief Executive Officer. "Our robust Phase 3 trials for D-PLEX$_{100}$ for the prevention of SSIs, SHIELD I and SHIELD II, continue to enroll patients at the expected rate. To this end, we are thrilled to report that the recruitment rate in SHIELD I trial doubled in the last three weeks and that we have now enrolled nearly 200 patients in the trial. We continue to anticipate the availability of top-line results for SHIELD I by year-end 2021 and top-line results from SHIELD II by the end of next year."

"We also continue to generate additional compelling preclinical data with OncoPLEX, including positive safety data in a promising solid tumor indication," continued Mr. Weisberg. "We are excited to further progress our OncoPLEX development program and potentially initiate a first-in-man Phase 1 clinical trial in 2022."

"Our strong balance sheet continues to drive our robust clinical development program. Our cash runway extends into 2022 and we remain well-positioned to complete the SHIELD I study and conduct SHIELD II, as well as prepare for the submission of a New Drug Application to the FDA with cash on hand," concluded Mr. Weisberg.

Financial results for three months ended March 31, 2021

- Research and development expenses for the three months ended March 31, 2021 were $6.0 million, compared to $3.4 million in the same three-month period of 2020, as spending increased due to the ongoing SHIELD I and SHIELD II Phase 3 clinical trials in abdominal surgery.
- Marketing and business development expenses for the three months ended March 31, 2021 were $0.7 million, compared to $0.3 million for the same period of 2020, as spending increased primarily due to additional marketing and business development personnel hired in the Company's New Jersey offices.
- General and administrative expenses for the three months ended March 31, 2021 were $2.1 million, compared to $0.7 million for the same period of 2020. This increase was due to the increase in costs due to the Company's status as a publicly traded company with higher D&O insurance costs and an increase in non-cash share-based compensation.
- For the three months ended March 31, 2021, the Company had a net loss attributable to ordinary shares of $8.7 million, compared to a net loss of $5.9 million, in the three-month period ended March 31, 2020.
- As of March 31, 2021, the Company had cash and cash equivalents, short-term deposits and long-term deposits in the amount of $61.4 million, compared to $66.6 million at December 31, 2020. PolyPid continues to expect that this cash balance will be sufficient to fund operations into 2022.

Conference Call Dial-In & Webcast Information:

Date:	Wednesday, May 12, 2021
Time:	8:30 AM Eastern Time
United States:	+1 877-870-9135
Israel:	+972 1809 213-985
International:	+44 (0) 2071 928338
Conference ID:	7258907
Webcast:	https://edge.media-server.com/mmc/p/j63c5h43

About D-PLEX$_{100}$

PolyPid's lead product candidate, D-PLEX$_{100}$, is a novel drug product candidate designed to provide local prolonged and controlled anti-bacterial activity directly at the surgical site to prevent SSIs. Following the administration of D-PLEX$_{100}$ into the surgical site, the PLEX technology enables a prolonged and constant release of the broad-spectrum antibiotic doxycycline, resulting in high local concentration of the drug for a period of four weeks for the prevention of SSIs, with additional potential to prevent SSIs caused by antibiotic-resistant bacteria at the surgical site. D-PLEX$_{100}$ has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the prevention of SSIs in patients undergoing elective colorectal surgery. D-PLEX$_{100}$ has also received two Qualified Infectious Disease Product (QIDP) designations as well as two Fast Track designations for the prevention of post-abdominal surgery incisional infection and for the prevention of sternal wound infection post-cardiac surgery.

About PolyPid

PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics. PolyPid's proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with medications, enables precise delivery of drugs at effective release rates, over durations ranging from several days to months. PolyPid's lead product candidate D-PLEX$_{100}$ is in Phase 3 clinical trials for the prevention of sternal and abdominal surgical site infections (SSIs).

For additional company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn.

Forward-looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses statements relating to the expected recruitment for trials, timing of trials and release of the results thereof, the capacity of the Company's manufacturing facility, the potential benefits of PLEX and OncoPLEX, the sufficiency of the Company's cash to fund future operations, and all statements (other than statements of historical facts) that address activities, events, or developments that the Company intends, expects, projects, believes, or anticipates will or may occur in the future. Forward-looking statements are not historical facts, and are based upon management's current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management's expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company's reports filed from time to time with the Securities and Exchange Commission ("SEC"), including, but not limited to, the risks detailed in the Company's Annual Report on Form 20-F filed on March 5, 2021. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements.

References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites.

Contacts:

PolyPid, Ltd.

Dikla Czaczkes Akselbrad

EVP & CFO

Tel: +972-747195700

Investors:

Bob Yedid

LifeSci Advisors

646-597-6989

Bob@LifeSciAdvisors.com

CONSOLIDATED BALANCE SHEETS

U.S. dollars in thousands

	March 31, 2021 Unaudited	December 31, 2020 Audited
	U.S. dollars in thousands	
ASSETS		
CURRENT ASSETS:		
Cash and cash equivalents	$ 5,993	$ 4,319
Restricted cash	385	390
Short-term deposits	43,279	40,157
Prepaid expenses and other receivables	1,286	2,334
Total current assets	50,943	47,200
LONG-TERM ASSETS:		
Property and equipment, net	6,023	5,890
Long-term deposits	12,100	22,120
Other long-term assets	773	637
Total long-term assets	18,896	28,647

Total assets	69,839	75,847

CONSOLIDATED BALANCE SHEETS
U.S. dollars in thousands (except share and per share data)

	March 31, 2021	December 31, 2020
	Unaudited	Audited
	U.S. dollars in thousands	
LIABILITIES, CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS' EQUITY		
CURRENT LIABILITIES:		
Trade payables	$ 1,468	$ 974
Other payables and accrued expenses	2,038	1,903
Total current liabilities	3,506	2,877
Long-term liabilities:		
Other liabilities	186	193
Total long-term liabilities	186	193
Commitments and Contingencies		
Shareholders' equity:		
Share capital -		
Ordinary shares with no par value - Authorized: 47,800,000 shares at March 31, 2021 (unaudited) and December 31, 2020; Issued and outstanding: 18,745,142 and 18,494,739 shares at March 31, 2021 (unaudited) and December 31, 2020, respectively.	-	-
Additional paid-in capital	207,120	205,063

Accumulated deficit	(140,973)	(132,286)
Total shareholders' equity	66,147	72,777
Total liabilities, convertible preferred shares and shareholders' equity	$ 69,839	$ 75,847

CONSOLIDATED STATEMENTS OF OPERATIONS

U.S. dollars in thousands (except share and per share data)

	Three months ended March 31,	
	2021	**2020**
	Unaudited	
	U.S. dollars in thousands	
Operating expenses:		
Research and development, net	$ 6,018	$ 3,433
Marketing and business development expenses	652	276
General and administrative	2,127	727
Operating loss	8,797	4,436
Financial expense (income), net	(110)	1,433
Net loss	$ 8,687	$ 5,869
Net loss attributable to Ordinary shares	$ 8,687	$ 5,869
Basic and diluted net loss per Ordinary share	$ 0.47	$ 13.90
Weighted average number of Ordinary shares used in computing basic and diluted net loss per share	18,623,154	562,748

`